Cite
Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation
MLA
Fradley, Michael, et al. “Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 10983–84. EBSCOhost, https://doi.org/10.1182/blood-2022-162797.
APA
Fradley, M., Lafeuille, M.-H., Emond, B., Crawford, S., Chen, N., Volodarsky, R., Nielsen, J., & Srivastava, B. P. (2022). Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation. Blood, 140(Supplement 1), 10983–10984. https://doi.org/10.1182/blood-2022-162797
Chicago
Fradley, Michael, Marie-Hélène Lafeuille, Bruno Emond, Samuel Crawford, Naijun Chen, Raisa Volodarsky, Jacqueline Nielsen, and Bhavini Patel Srivastava. 2022. “Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation.” Blood 140 (Supplement 1): 10983–84. doi:10.1182/blood-2022-162797.